US FDA approves Arcutis’ drug for the treatment of chronic skin conditions
The US Food and Drug Administration has approved Arcutis Biotherapeutics’ drug to treat a skin condition called seborrheic dermatitis in people aged nine and older. Arcutis shares jumped 20 per cent in extended trading to $2.94.
POPULAR POSTS
‘The Kardashians’ renewed by Hulu for 20 more episodes
July 26, 2024
Death toll from landslides in Ethiopia could rise to 500
July 26, 2024
The Canadian wildfire has made its way to Jasper
July 26, 2024
LIVE STREAM